The Next Wave of Life Sciences M&A

The next wave of life sciences M&A demands precision.

Life sciences dealmaking is back on the offense. Breakthroughs in biotechnology, metabolic health, and AI have restored momentum—and sharpened expectations.

But higher velocity comes with higher scrutiny. Policy shifts, pricing pressure, and rising digital maturity standards are rewriting how value is created, measured, and protected. Success now depends on execution, not optimism.

How the next wave of life sciences M&A will unfold

• Dealmaking is rebounding, but advantage now goes to acquirers who can turn scientific potential into performance.
• Policy volatility is reshaping diligence and valuation as tariffs, pricing reform, and MAHA accelerate change.
• Innovation is expanding, but financial discipline and AI-driven disruption are redefining where investment flows.
• Services platforms are emerging as the sector’s connective tissue as private equity leans harder into life sciences.
• AI maturity has become a proxy for integration readiness and post-close value creation.